We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
AstraZeneca is already considering offloading MedImmune's vaccines business, just days after it paid $15.2bn (£7.6bn, E11.2bn) for the US biotech. Read More
Novartis AG said Wednesday it will pay Cytos Biotechnology AG up to 600 million Swiss francs (US$500 million; 366 million) for the exclusive right to develop, produce and market an experimental drug it hopes will help cure smokers of their habit. Read More
The military spends billions of dollars annually in partnerships with medical devicemakers, particularly in the areas of R&D and
acquisition, David Hood, senior adviser for the Army's Medical
Research and Material Command (MRMC), said.
As part of a legal settlement, Novartis will assist Bayer Schering Pharma in obtaining FDA validation of Bayer’s outsourced European Betaseron manufacturing facility, Bayer told DID March 27.
Schering-Plough and Merck have announced an agreement to jointly develop a fixed-dose cholesterol drug that will combine Zetia and atorvastatin, which sold by Pfizer under the brand name Lipitor.
Sales of buproprion hydrochloride extended-release are expected to continue for two more months, according a new agreement aimed at resolving patent litigation brought by Biovail to block generic versions of its antidepressant drug, Wellbutrin XL.
Schering-Plough is buying Organon BioSciences, the human and animal healthcare unit of Akzo Nobel, for $14.4 billion to supplement its late-stage product pipeline, the company announced.
Shire Laboratories’ plan to acquire a smaller specialty drug manufacturer, giving it full control of the marketing and manufacturing of the attention-deficit/hyperactivity disorder (ADHD) drug Vyvanse, could put it in the same market as generic Adderall XR, according to a company source.